en · de · es
ipamorelin-notes.peptides1126.com › Wiki › Ipamorelin Background And Mechanism — What the Evidence Shows

Ipamorelin Background And Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-09-12 · last reviewed 2025-10-09 · Wiki

GHS-R1a comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.

Ipamorelin Background and Mechanism

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

背景与分子特征

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Includes two non-natural residues
Molecular weightAbout 711.9 g/molConfirmed by mass spectrometry
AppearanceWhite to off-white powderTypical lyophilized form
Receptor targetGHS-R1aGhrelin receptor agonist
Plasma half-lifeRoughly 2 hoursVaries by species and assay

Receptor Mechanism and Secretagogue Action

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Related pages on this site

Background and Structural Identity

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

背景与受体作用机制

Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

在机制层面,ipamorelin 与生长激素促分泌受体 1a 型结合,该受体也介导胃饥饿素的多种效应。受体激活后,细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱,它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到,但人体数据仍然有限。

Receptor Selectivity and Secretagogue Signaling

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Reference notes

== Rhenium-186 == Rhenium-186 is a low-energy beta emitter and radiopharmaceutical that is used to treat glioblastoma, is used in theranostic medicine and has been reported to be used in synoviorthesis. The maximum tissue penetration of 186Re is 4.5mm, making it a promising candidate for therapy of tumors with millimeter to centimeter dimensions. It also emits a low-abundance gamma ray with an energy of 137keV, which make it useful for SPECT dosimetry studies and in-vivo imaging of radio-labelled biomolecules. A radiopharmaceutical containing 186Re, tin, and HEDP was found to localize in painful skeletal metastasizes and ease pain for about 80% of patients.

=== Both === Amylin analogues can both reduce energy intake and increase expenditure and can usefully be combined with leptin analogues for synergistic effect. The dual amylin and calcitonin receptor agonist cagrilintide, in combination with semaglutide, was more effective than semaglutide alone in promoting weight loss in clinical trials. Glucagon receptor agonists both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.

A nonsynonymous mutation that occurs at the genomic or transcriptional levels is one that results in an alteration to the amino acid sequence in the protein product. A protein's primary structure refers to its amino acid sequence. A substitution of one amino acid for another can impair protein function and tertiary structure, however its effects may be minimal or tolerated depending on how closely the properties of the amino acids involved in the swap correlate. The premature insertion of a stop codon, a nonsense mutation, can alter the primary structure of a protein. In this case, a truncated protein is produced. Protein function and folding is dependent on the position in which the stop codon was inserted and the amount and composition of the sequence lost. Conversely, silent mutations are mutations in which the amino acid sequence is not altered. Silent mutations lead to a change of one of the letters in the triplet code that represents a codon, but despite the single base change, the amino acid that is coded for remains unchanged or similar in biochemical properties. This is permitted by the degeneracy of the genetic code. Historically, silent mutations were thought to be of little to no significance. However, recent research suggests that such alterations to the triplet code do affect protein translation efficiency and protein folding and function. Furthermore, a change in primary structure is critical because the fully folded tertiary structure of a protein is dependent upon the primary structure.

Sources: en.wikipedia.org

Reference notes

===== Indirect method ===== Another variation of Roselius' method is the indirect organic solvent method. In this method, instead of treating the beans directly, they are first soaked in hot water for several hours, then removed. The remaining water is treated with solvents (e.g. dichloromethane or ethyl acetate) to extract the caffeine from the water. As in other methods, the caffeine can then be separated from the organic solvent by simple evaporation. The same water is recycled through this two-step process with new batches of beans. An equilibrium is reached after several cycles, wherein the water and the beans have a similar composition except for the caffeine. After this point, the caffeine is the only material removed from the beans, so no coffee strength or other flavorings are lost. Because water is used in the initial phase of this process, indirect method decaffeination is sometimes referred to as "water-processed". This method was first mentioned in 1941, and scientists have made significant efforts to make the process more "natural" and a true water-based process by finding ways to process the caffeine out of the water in ways that circumvent the use of organic solvents.

== Chemically modified nucleotides == Recently, SELEX has expanded to include the use of chemically modified nucleotides. These chemically modified oligonucleotides offer many potential advantages for selected aptamers including greater stability and nuclease resistance, enhanced binding for select targets, expanded physical properties - like increased hydrophobicity, and more diverse structural conformations. The genetic alphabet, and thus possible aptamers, is also expanded using unnatural base pairs the use of these unnatural base pairs was applied to SELEX and high affinity DNA aptamers were generated.

During his 2022 gubernatorial campaign, Moore said he supported the Inclusive Schools Act, a bill introduced in the 2022 legislative session that banned schools from discriminating against students based on their sexual orientation and gender identity. He also supported the Trans Health Equity Act, a bill that would have required the state's Medicaid program to cover gender-affirming treatments. In December 2022, Moore praised the signing of the Respect for Marriage Act, which codifies same-sex and interracial marriage rights. On March 31, 2023, Moore became the first Maryland governor to recognize International Transgender Day of Visibility when he issued an official proclamation. In May 2023, Moore signed the Trans Health Equity Act into law and allowed a bill furthering an earlier repeal of the state's sodomy law to become law without his signature. In June 2023, he signed an executive order to protect people or entities that provide gender-affirming care from legal punishments by other states. During the 2024 legislative session, Moore signed into law the Trans Shield Act, which prevents states with anti-trans laws from prosecuting patients or entities within Maryland for providing gender-affirming care. In May 2025, Moore signed into law a bill decriminalizing the spread of HIV.

Sources: en.wikipedia.org

Reference notes

Deupsilocin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code names HLP003 and CYB0003), also known as deuterated psilocin or as psilocin-d10, is a psychedelic drug of the tryptamine family related to psilocin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is taken orally. The drug is a deuterated isotopologue of psilocin with altered pharmacokinetics.

Umami ( from Japanese: うま味, pronounced [ɯmami]), or savoriness, is one of the five basic tastes. It is characteristic of broths and cooked meats. People taste umami through taste receptors that typically respond to glutamates and nucleotides, which are widely present in meat broths and fermented products. Glutamates are commonly added to some foods in the form of monosodium glutamate (MSG), and nucleotides are commonly added in the form of disodium guanylate, inosine monophosphate (IMP) or guanosine monophosphate (GMP). Since umami has its own receptors rather than arising out of a combination of the traditionally recognized taste receptors, scientists now consider umami to be a distinct taste. Food, beverages, or condiments that have a strong umami flavor include meats, shellfish, fish (including fish sauce and preserved fish such as Maldives fish, katsuobushi, sardines, and anchovies), dashi, tomatoes, mushrooms, hydrolyzed vegetable protein, meat extract (Bouillon cubes), yeast extract (beer, Marmite, Vegemite), kimchi, cheeses (Parmesan, Asiago cheese, or blue cheese), as well as sauces such as A1 sauce, Worcestershire sauce, and soy sauce. In 1908, Kikunae Ikeda of the University of Tokyo scientifically identified umami as a distinct taste attributed to glutamic acid. As a result, in 1909, Ikeda and Saburōsuke Suzuki founded Ajinomoto Co., Inc.

There is a choroid plexus in each of the four ventricles. In the lateral ventricles, it is found in the body, and continued in an enlarged amount in the atrium. There is no choroid plexus in the anterior horn. In the third ventricle, there is a small amount in the roof that is continuous with that in the body, via the interventricular foramina, the channels that connect the lateral ventricles with the third ventricle. A choroid plexus is in part of the roof of the fourth ventricle.

Sources: en.wikipedia.org

Frequently asked questions

What is the amino acid sequence of ipamorelin?

The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.

How does ipamorelin differ from earlier growth hormone secretagogues?

It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.

Is ipamorelin an approved medicine?

No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.

Ipamorelin 与 GHRP-6 有什么不同?

两者都是 GHS-R1a 激动剂,但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度,而非绝对区分。

Network